ClinicalTrials.gg

TargetBeta

CD276

CD276 molecule · also B7-H3, B7H3, B7RP-2 · CD molecules

13 programs in company-led studies act on CD276, from 13 companies: 7 in phase 3. Each with where its target was read from.

Programs

Furthest phase first. A target read by rule is marked rule (8 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.

ProgramCompanyFurthest phaseStudiesAlso acts onRead from
risvutatug rezetecanHansoh Pharmaceutical Groupphase 33026 running–the company's pipeline
ifinatamab deruxtecanMerckphase 31616 running–the company's pipeline
tambotatug pelitecanMediLink Therapeutics (Suzhou)phase 31313 running–a judged reading
Anti-B7-H3/TOP1i Antibody-drug Conjugate SYS6043CSPC Pharmaceutical Groupphase 355 running–a judged reading
Anti-B7-H3 Antibody-drug Conjugate MHB088CruleMinghui Pharmaceuticalphase 344 running–NCIt
Elfetabart DrozuntecanruleBioNTechphase 333 running–NCIt
Anti-EGFR/Anti-B7-H3 Bispecific Antibody-drug Conjugate TJ101ruleTJ Biopharmaphase 331 runningEGFRNCIt
Autologous Anti-B7-H3 CAR T-cells BCB-276ruleBrainChild Biophase 211 running–NCIt
Lutetium Lu 177-DOTA-Anti-B7-H3 Monoclonal Antibody RV-01ruleRadiopharm Theranosticsphase 211 running–NCIt
Anti-B7-H3/CD28 Bispecific Antibody XmAb808ruleXencorphase 121 runningCD28NCIt
Anti-B7-H3/Anti-PTK7-TOP1i Bispecific Antibody-drug Conjugate IDE034ruleIDEAYA Biosciencesphase 111 runningPTK7NCIt
Anti-B7-H3/Anti-ROR1-Exatecan Bispecific Antibody-drug Conjugate NEOK001ruleNEOK Biophase 111 runningROR1NCIt
HLX316Fosun Pharmaphase 111 running–the company's pipeline

Also acted on by the same programs

Primary completions ahead

Each program’s next study to reach its primary completion, by the sponsor’s estimate.

What this can’t show

  • Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
  • A target read by rule can be wrong; each program’s page quotes the words it was read from.
  • “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
  • Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.